The Interleukin 6 (IL-6) blockade for coronavirus disease 2019 (COVID-19) In Lung

Zhili Rao[1], Hongli Zhou[2], Xiangyu Li[1], and Nan Zeng[3]

[1]Department of Pharmacology, College of Pharmacy, Chengdu University of Traditional Chinese Medicine,Chengdu city, Sichuan Province, Chengdu 611137, PR China
[2]National Drug Clinical Trial Institution, the Second Affiliated Hospital, Army Medical University, Chongqing 400037, China.
[3]Chengdu University of Traditional Chinese Medicine

April 05, 2024

Abstract

COVID-19 has caused global pandemics since the emergent outbreak and resulted in a large number of deaths. IL-6, as an important autoimmune cytokine, had been suggested for the treatment of acute respiratory distress syndrome (ARDS) patients in COVID-19. A review of the relevant literature revealed more than one role for IL-6 in the lung infection because of its diverse biological effects. It may have a variety of different physiological functions in the development of lung infection. We have summarized its role in different progress of COVID-19, including lung infection, pneumonia, ALI, pulmonary fibrosis, and lung translation and even lung cancer. This will facilitate a deeper understanding of the role of IL-6 in the treatment of COVID-19.

Hosted file

manucript.docx available at https://authorea.com/users/733538/articles/711164-the-interleukin-6-il-6-blockade-for-coronavirus-disease-2019-covid-19-in-lung